Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

dc.contributor.authorOzdogu, Hakan
dc.contributor.orcID0000-0002-8902-1283en_US
dc.contributor.pubmedID31926364en_US
dc.contributor.researcherIDAAD-5542-2021en_US
dc.date.accessioned2021-06-17T07:41:28Z
dc.date.available2021-06-17T07:41:28Z
dc.date.issued2020
dc.description.abstractAllogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem cell donation. However, data are scarce on predictive factors for outcome in that setting. We identified 122 adults (20% female; median age, 31 years; range, 18 to 68 years) with T-ALL who underwent haplo-HCT with post-transplantation cyclophosphamide (ptCy) between 2010 and 2017. The median duration of follow-up of living patients was 23 months. The 2-year incidences of relapse and nonrelapse mortality were 45% and 21%, respectively. The 2-year leukemia-free survival (LFS), overall survival (OS), and graft-versushost disease, relapse-free survival (GRFS) were 34%, 42%, and 27%, respectively. The 2-year LFS and OS were highly influenced by disease status at transplantation, being 49% and 55%, respectively, for patients in first complete remission (CR1); 34% and 50%, respectively, for those in second CR (CR2); and 8% and 12%, respectively, for patients with active disease. On multivariate analysis, only disease status was found to affect LFS and OS. Transplantation in CR2 negatively affected LFS, whereas active disease at the time of haplo-HCT negatively affected LFS and OS. In conclusion, haplo-HCT with ptCy produced encouraging results in this challenging disease, particularly when performed in patients in CR. Despite the limitation of the small sample size, our results were not affected by the type of conditioning, calling into question the need for total body irradiation-based myeloablative conditioning in that setting. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.en_US
dc.identifier.endpage942en_US
dc.identifier.issn1083-8791en_US
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-85080084689en_US
dc.identifier.startpage936en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1083879120300136?via%3Dihub
dc.identifier.urihttp://hdl.handle.net/11727/6083
dc.identifier.volume26en_US
dc.identifier.wos000531098000020en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.bbmt.2020.01.003en_US
dc.relation.journalBIOLOGY OF BLOOD AND MARROW TRANSPLANTATIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConditioningen_US
dc.subjectHaploidentical stem cell transplantationen_US
dc.subjectT-ALLen_US
dc.subjectThiotepaen_US
dc.subjectTotal body irradiationen_US
dc.titleHaploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Partyen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S1083879120300136-main.pdf
Size:
646.58 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: